Vergoeding 2020-2024 voor ATC-subgroep L01EA : Bcr-abl-tyrosinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L01EA01 Imatinib | 10.318.671 | 8.709.710 | 2.558.770 | 2.220.970 | 1.313.286 |
| L01EA02 Dasatinib | 15.945.772 | 13.749.055 | 12.489.184 | 4.564.455 | 2.167.414 |
| L01EA03 Nilotinib | 11.488.565 | 9.927.758 | 8.467.679 | 7.773.622 | 6.069.474 |
| L01EA04 Bosutinib | 2.886.077 | 3.304.610 | 3.267.928 | 3.428.903 | 3.261.749 |
| L01EA05 Ponatinib | 2.962.238 | 3.191.722 | 2.507.659 | 2.956.456 | 2.630.208 |
| L01EA06 Asciminib | . | . | . | 2.179.751 | 2.561.637 |
| Totaal | 43.601.324 | 38.882.854 | 29.291.221 | 23.124.157 | 18.003.769 |